Metys Pharmaceuticals
VerifiedDeveloping dimiracetam for the prevention of chemotherapy-induced painful peripheral neuropathy.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$5—7m (Dealroom.co estimates Oct 2013.)
Company register number CH-270.3.014.848-3
Basel Canton of Basel-Stadt (HQ)
| EUR | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 1 % | (8 %) | 4 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $0.0 | round | |
| investor | $0.0 | round | |
N/A | Acquisition | ||
| Total Funding | 000k | ||
RELATED LANDSCAPES AND LISTS
Related Content
Recent News about Metys Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.